Trovagene adds Duke University Health System to worldwide licensees of NPM1 marker for AML

Dec 27 2012

Trovagene, Inc. (NASDAQ:  TROV), a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health Systems a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia (AML). Trovagene holds an exclusive worldwide license to U.S. patent 8,222,370 and the corresponding group of U.S. and foreign patent applications around NPM1. Terms of the agreement include upfront fees and royalty payments. Additional financial terms were not disclosed.

"Trovagene is pleased to add Duke University Health System to its list of worldwide licensees of the NPM1 marker," said Antonius Schuh, Ph.D., chief executive officer for Trovagene. "Use of NPM1 is part of the NCCN guidelines for the treatment of AML.  Clinical and academic laboratories are increasingly interested in licensing this assay so they can offer it directly to their physicians for use in patient care."

Within the United States, Trovagene has granted non-exclusive sublicenses to offer mutation analysis of NPM1 as a laboratory service for the diagnosis and monitoring of patients with AML to Quest Diagnostics, LabCorp, Fairview Health Services and Invivoscribe Technologies; internationally, license holders include Münchner Leukamielabor GmbH (MLL) in Munich, Germany and Skyline Labs in the Netherlands. In addition, Trovagene has granted a co-exclusive license to manufacture and sell NPM1 mutation kits to Asuragen, Inc. and Ipsogen S.A.

Laboratories interested in obtaining a license for testing NPM1 mutations for AML patients should contact Trovagene directly at 888-391-7992.

SOURCE Trovagene, Inc.